美国国立卫生研究院资助的一项研究发现，司美格鲁肽——即减肥药物Ozempic和Wegovy的活性成分——在老年小鼠中展现出延缓衰老的潜力。1由加州大学伯克利分校的Danica Chen博士领导的研究团队发现，这一药物不仅改善了小鼠的记忆、肌肉功能和血糖控制，其抗衰老效果还超越了热量限制饮食的效果，表明GLP-1类药物可能通过独立于饮食的生物学途径影响衰老过程。1
在实验中，司美格鲁肽使20月龄小鼠的中位寿命延长了近100天。1经过三个月的给药治疗后，接受该药物的小鼠在肌肉和认知功能方面均有改善。1与实施24%热量限制饮食的对照组相比，司美格鲁肽组小鼠在探索行为、空间记忆和血糖维持方面表现更优。1值得注意的是，接受司美格鲁肽治疗的小鼠代谢率基本保持不变，而热量限制组的代谢速率明显下降。1
该研究已发表于《自然》杂志2026年657卷8131期。1研究人员表示，需要进一步的临床研究来确定这些效果是否能够转化为对人类的治疗价值。1
Researchers supported by the National Institutes of Health have discovered that semaglutide, the active ingredient in Ozempic and Wegovy, extends lifespan and reduces signs of aging in elderly mice.1 The study, led by Dr. Danica Chen at UC Berkeley and published in Nature in 2026, demonstrated that the drug improved memory, muscle function, and blood sugar control while producing anti-aging effects that surpassed those achieved through caloric restriction alone.1
In the trial, semaglutide extended median lifespan by nearly 100 days in 20-month-old mice.1 After three months of treatment, mice receiving semaglutide showed improvements in both muscle and cognitive function.1 When compared to mice on a 24% calorie-restricted diet, semaglutide-treated mice performed better in exploratory behavior, spatial memory, and blood glucose maintenance.1 Notably, mice treated with semaglutide maintained relatively stable metabolic rates, whereas those on calorie-restricted diets experienced decreased metabolic speed.1 These findings suggest that GLP-1 drugs may influence the aging process through biological pathways independent of dietary intervention.1
However, researchers emphasized that further clinical studies are needed to determine whether these effects can be translated to humans.1
评论
还没有评论，欢迎留下第一条。